Unraveling oxyntomodulin, GLP1's enigmatic brother

Journal of Endocrinology

Volumn 215, Issue 3, 2012, Pages 335-346

  Pocai, Alessandro ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON RECEPTOR; GLUCOSE; OXYNTOMODULIN; PREPROGLUCAGON; UNCLASSIFIED DRUG; ZP2929;

APPETITE; BODY WEIGHT; DRUG HALF LIFE; ENERGY EXPENDITURE; GASTRIC BANDING; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; STOMACH BYPASS; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; OBESITY; OXYNTOMODULIN; RECEPTORS, GLUCAGON;

EID: 84872175094     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0368     Document Type: Review

References (149)

1. Abu Fanne R, Banai S, Chorin U, Rogowski O, Keren G & Roth A 2011 Diagnostic yield of extensive infectious panel testing in acute pericarditis. Cardiology 119 134-139. (doi:10.1159/000330928)
2. Ahren B 2004 Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 286 R269-R272. (doi:10.1152/ajpregu. 00423.2003)
3. Amir S 1986 Central glucagon-induced hyperglycemia is mediated by combined activation of the adrenal medulla and sympathetic nerve endings. Physiology and Behavior 37 563-566. (doi:10.1016/0031-9384(86)90286-6)
4. Amori RE, Lau J & Pittas AG 2007 Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Journal of the American Medical Association 298 194-206. (doi:10.1001/jama.298.2.194)
5. Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J & Roz C 1999 Comparison of the postprandial release of peptide YY and proglucagonderived peptides in the rat. Pflu¨gers Archiv 438 299-306. (doi:10.1007/ s004240050913)
6. Anini Y, Jarrousse C, Chariot J, Nagain C, Yanaihara N, Sasaki K, Bernad N, Le Nguyen D, Bataille D & Roze C 2000 Oxyntomodulin inhibits pancreatic secretion through the nervous system in rats. Pancreas 20 348-360. (doi:10.1097/00006676-200005000-00003)
7. Ashrafian H, Athanasiou T, Li JV, Bueter M, Ahmed K, Nagpal K, Holmes E, Darzi A & Bloom SR 2011 Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obesity Reviews 12 e257-e272. (doi:10.1111/j.1467-789X.2010.00802.x)
8. Astrup A, Carraro R, FinerN, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rossner S et al. 2012 Safety, tolerability and sustained weight loss over 2 yearswith the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity 36 843-854. (doi:10.1038/ ijo.2011.158)
9. Axelsen LN,KeungW, PedersenHD,Meier E, RiberD,Kjolbye AL,Petersen JS, Proctor SD, Holstein-Rathlou NH & Lopaschuk GD 2012 Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts. British Journal of Pharmacology 165 2736-2748. (doi:10.1111/j.1476-5381.2011.01714.x)
10. Baggio LL & Drucker DJ 2007 Biology of incretins: GLP-1 and GIP. Gastroenterology 132 2131-2157. (doi:10.1053/j.gastro.2007.03.054)
11. Baggio LL, Huang Q, Brown TJ & Drucker DJ 2004 Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127 546-558. (doi:10.1053/j.gastro. 2004.04.063)
12. Baldissera FG & Holst JJ 1984 Glucagon-related peptides in the human gastrointestinal mucosa. Diabetologia 26 223-228. (doi:10.1007/ BF00252412)
13. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L & Nielsen OV 1988 Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regulatory Peptides 21 151-166. (doi:10.1016/0167-0115(88)90099-7)
14. Barbato A, Russo P, Venezia A, Strazzullo V, Siani A & Cappuccio FP 2003 Analysis of Gly40Ser polymorphism of the glucagon receptor (GCGR) gene in different ethnic groups. Journal of Human Hypertension 17 577-579. (doi:10.1038/sj.jhh.1001591)
15. Bataille D, Gespach C, Coudray AM & Rosselin G 1981a 'Enteroglucagon': a specific effect on gastric glands isolated from the rat fundus. Evidence for an 'oxyntomodulin' action. Bioscience Reports 1 151-155. (doi:10.1007/ BF01117012)
16. Bataille D, Gespach C, Tatemoto K, Marie JC, Coudray AM, Rosselin G & Mutt V 1981b Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides 2 (Suppl 2) 41-44. (doi:10.1016/0196-9781(81)90008-5)
17. Bataille D, Tatemoto K, Coudray AM, Rosselin G & Mutt V 1981c Bioactive 'enteroglucagon' (oxyntomodulin): evidence for a C-terminal extension of the glucagon molecule. Comptes Rendus des Se´ances de l'Académie des Sciences. Se´rie III, Sciences de la Vie 293 323-328.
18. Bataille D, Tatemoto K, Gespach C, Jornvall H, Rosselin G & Mutt V 1982 Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Letters 146 79-86. (doi:10.1016/0014-5793(82)80709-6)
19. Besterman HS, Cook GC, Sarson DL, Christofides ND, Bryant MG, Gregor M & Bloom SR 1979 Gut hormones in tropical malabsorption. BMJ 2 1252-1255. (doi:10.1136/bmj.2.6200.1252)
20. Besterman HS, Adrian TE, Mallinson CN, Christofides ND, Sarson DL, Pera A, Lombardo L, Modigliani R & Bloom SR 1982 Gut hormone release after intestinal resection. Gut 23 854-861. (doi:10.1136/gut.23. 10.854)
21. Biedzinski TM, Bataille D, Devaux MA & Sarles H 1987 The effect of oxyntomodulin (glucagon-37) and glucagon on exocrine pancreatic secretion in the conscious rat. Peptides 8 967-972. (doi:10.1016/0196- 9781(87)90122-7)
22. Blache P, Kervran A, Martinez J & Bataille D 1988 Development of an oxyntomodulin/glicentin C-terminal radioimmunoassay using a 'thiolmaleoyl' coupling method for preparing the immunogen. Analytical Biochemistry 173 151-159. (doi:10.1016/0003-2697(88)90172-8)
23. Bray GA 2004 Medical consequences of obesity. Journal of Clinical Endocrinology and Metabolism 89 2583-2589. (doi:10.1210/jc.2004-0535)
24. Brubaker PL 2012 A beautiful cell (or two or three?) Endocrinology 153 2945-2948. (doi:10.1210/en.2012-1549)
25. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH & Drucker DJ 1997 Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 138 4837-4843. (doi:10.1210/en.138.11.4837)
26. Buse MG, Biggers JF, Drier C & Buse JF 1973 The effect of epinephrine, glucagon, and the nutritional state on the oxidation of branched chain amino acids and pyruvate by isolated hearts and diaphragms of the rat. Journal of Biological Chemistry 248 697-706.
27. Campos RV, Lee YC & Drucker DJ 1994 Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134 2156-2164. (doi:10.1210/ en.134.5.2156)
28. Chandarana K & Batterham RL 2012 Shedding pounds after going under the knife: metabolic insights from cutting the gut. Nature Medicine 18 668-669. (doi:10.1038/nm.2748)
29. Chaudhri OB, Parkinson JR, Kuo YT, Druce MR, Herlihy AH, Bell JD, Dhillo WS, Stanley SA, Ghatei MA & Bloom SR 2006 Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochemical and Biophysical Research Communications 350 298-306. (doi:10.1016/j.bbrc.2006.09.033)
30. Collie NL, Zhu Z, Jordan S & Reeve JR Jr 1997 Oxyntomodulin stimulates intestinal glucose uptake in rats. Gastroenterology 112 1961-1970. (doi:10.1053/gast.1997.v112.pm9178688)
31. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA & Bloom SR 2001 Oxyntomodulin inhibits food intake in the rat. Endocrinology 142 4244-4250. (doi:10.1210/en.142.10.4244)
32. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA & Bloom SR 2004 Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145 2687-2695. (doi:10.1210/en.2003-1338)
33. D'Alessio D 2008 Intestinal hormones and regulation of satiety: the case for CCK, GLP-1, PYY, and Apo A-IV. JPEN. Journal of Parenteral and Enteral Nutrition 32 567-568. (doi:10.1177/0148607108322401)
34. D'Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F & Paolisso G 2010 Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Experimental Gerontology 45 202-207. (doi:10.1016/j.exger.2009.12.004)
35. Day JW, OttawayN, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N et al. 2009 A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology 5 749-757. (doi:10.1038/nchembio.209)
36. Day JW, Smiley D, Carrington PE, Eiermann G, Chicchi G, Erion MD, Gidda J, Thornberry NA, Tschöp MH, Marsh DJ et al. 2012 Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Peptide Science 98 443-450. (doi:10.1002/bip. 22072)
37. Deacon CF 2005 What do we know about the secretion and degradation of incretin hormones? Regulatory Peptides 128 117-124. (doi:10.1016/ j.regpep.2004.06.007)
38. Derosa G & Maffioli P 2012 Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technology and Therapeutics 14 350-364. (doi:10.1089/ dia.2011.0204)
39. Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF & Maffioli P 2012a Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, b-cell function and insulin resistance in type 2 diabetic patients. Diabetes Research and Clinical Practice 98 51-60. (doi:10.1016/j. diabres.2012.05.022)
40. Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF & Maffioli P 2012b Vildagliptin added to metformin on b-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technology and Therapeutics 14 475-484. (doi:10.1089/dia.2011.0278)
41. Druce MR & Bloom SR 2006 Oxyntomodulin: a novel potential treatment for obesity. Treatments in Endocrinology 5 265-272. (doi:10.2165/00024677- 200605050-00001)
42. Drucker DJ 2005 Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Clinical Practice. Endocrinology and Metabolism 1 22-31. (doi:10.1038/ncpendmet0017)
43. Drucker DJ, Philippe J, Mojsov S, Chick WL & Habener JF 1987 Glucagonlike peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. PNAS 84 3434-3438. (doi:10.1073/ pnas.84.10.3434)
44. Drucker DJ, Dritselis A & Kirkpatrick P 2010 Liraglutide. Nature Reviews. Drug Discovery 9 267-268. (doi:10.1038/nrd3148)
45. Du X, Kosinski JR, Lao J, Shen X, Petrov A, Chicchi GG, Eiermann GJ & Pocai A 2012 Differential effects of oxyntomodulin and GLP-1 on glucose metabolism. American Journal of Physiology. Endocrinology and Metabolism 303 E265-E271. (doi:10.1152/ajpendo.00142.2012)
46. Dubrasquet M, Bataille D & Gespach C 1982 Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Bioscience Reports 2 391-395. (doi:10.1007/ BF01119301)
47. Engel SS, Xu L, Andryuk PJ, Davies MJ, Amatruda J, Kaufman K & Goldstein BJ 2011 Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM). Diabetes 60 (Suppl 1) A85. (doi:10.2337/db11-1-378)
48. Falken Y, Hellstrom PM, Holst JJ & Naslund E 2011 Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. Journal of Clinical Endocrinology and Metabolism 96 2227-2235. (doi:10.1210/ jc.2010-2876)
49. Farah A & Tuttle R 1960 Studies on the pharmacology of glucagon. Journal of Pharmacology and Experimental Therapeutics 129 49-55.
50. Field BC, Chaudhri OB & Bloom SR 2009 Obesity treatment: novel peripheral targets. British Journal of Clinical Pharmacology 68 830-843. (doi:10.1111/j.1365-2125.2009.03522.x)
51. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA et al. 2010 PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 59 1635-1639. (doi:10.2337/ db09-1859)
52. Flamez D, Gilon P, Moens K, Van Breusegem A, Delmeire D, Scrocchi LA, Henquin JC, Drucker DJ & Schuit F 1999 Altered cAMP and Ca2C signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 48 1979-1986. (doi:10.2337/diabetes.48.10.1979)
53. Fosgerau KS, Larsen M, BaeK SA, Meier E, Groendahl C & Bak HH 2011 Combination of long-acting insulin with the dual GluGLP-1 agonist ZP2929 causes improved glycemic control without body weight gain in db/db mice. Diabetes 60 (Suppl 1) A418. (doi:10.2337/db11-1487-1624)
54. Furuta M, Zhou A, Webb G, Carroll R, Ravazzola M, Orci L & Steiner DF 2001 Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. Journal of Biological Chemistry 276 27197-27202. (doi:10.1074/jbc.M103362200)
55. van Genugten RE, van Raalte DH & Diamant M 2012 Dipeptidyl peptidase- 4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes, Obesity and Metabolism 14 101-111. (doi:10.1111/j.1463-1326.2011.01473.x)
56. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG & Bloom SR 1983 Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. Journal of Clinical Endocrinology and Metabolism 57 488-495. (doi:10.1210/jcem-57-3-488)
57. Gonzalez-Munoz C, Nieto-Ceron S, Cabezas-Herrera J & Hernandez-Cascales J 2008 Glucagon increases contractility in ventricle but not in atrium of the rat heart. European Journal of Pharmacology 587 243-247. (doi:10.1016/j.ejphar.2008.04.001)
58. Grieve DJ, Cassidy RS & Green BD 2009 Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? British Journal of Pharmacology 157 1340-1351. (doi:10.1111/j.1476-5381.2009.00376.x)
59. Gros L, Thorens B, Bataille D & Kervran A 1993 Glucagon-like peptide- 1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 133 631-638. (doi:10.1210/en.133.2.631)
60. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R & Tschop MH 2010 The metabolic actions of glucagon revisited. Nature Reviews. Endocrinology 6 689-697. (doi:10.1038/nrendo.2010.187)
61. Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CA, Parker HE, Morley TC, Yeo GS, Reimann F & Gribble FM 2012 Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153 3054-3065. (doi:10.1210/ en.2011-2170)
62. Halquist MS, Sakagami M & Karnes HT 2012 Determination of oxyntomodulin, an anorectic polypeptide, in rat plasma using 2D-LC- MS/MS coupled with ion pair chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 903 102-111. (doi:10.1016/j.jchromb.2012.06.047)
63. Hansen L, Deacon CF, Orskov C & Holst JJ 1999 Glucagon-like peptide-1- (7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140 5356-5363. (doi:10.1210/en.140.11.5356)
64. Holscher C 2012 Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 26 871-882. (doi:10.2165/11635890- 000000000-00000)
65. Holst JJ 1982 Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochemical Journal 207 381-388.
66. Holst JJ 1983 Gut glucagon, enteroglucagon, gut glucagon-like immunoreactivity, glicentin - current status. Gastroenterology 84 1602-1613.
67. Holst JJ 1997 Enteroglucagon. Annual Review of Physiology 59 257-271. (doi:10.1146/annurev.physiol.59.1.257)
68. Holst JJ 2000 Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2. Regulatory Peptides 93 45-51. (doi:10.1016/S0167- 0115(00)00185-3)
69. Holst JJ 2007 The physiology of glucagon-like peptide 1. Physiological Reviews 87 1409-1439. (doi:10.1152/physrev.00034.2006)
70. Holst JJ, Christiansen J & Kuhl C 1976 The enteroglucagon response to intrajejunal infusion of glucose, triglycerides, and sodium chloride, and its relation to jejunal inhibition of gastric acid secretion in man. Scandinavian Journal of Gastroenterology 11 297-304.
71. Holst JJ, Sorensen TI, Andersen AN, Stadil F, Andersen B, Lauritsen KB & Klein HC 1979 Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scandinavian Journal of Gastroenterology 14 205-207. (doi:10.3109/00365527909179871)
72. Htike ZZ, Khunti K & Davies M 2012 A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. Diabetes Therapy 3 1-16. (doi:10.1007/s13300-012-0003-x)
73. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Goke R, Goke B, Thole H, Zimmermann B & Voigt K 1995 Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regulatory Peptides 58 149-156. (doi:10.1016/ 0167-0115(95)00063-H)
74. Hupe-Sodmann K, Goke R, Goke B, Thole HH, Zimmermann B, Voigt K & McGregor GP 1997 Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides 18 625-632. (doi:10.1016/S0196-9781(97)00123-X)
75. Jones BJ, Tan T & Bloom SR 2012 Minireview: glucagon in stress and energy homeostasis. Endocrinology 153 1049-1054. (doi:10.1210/en.2011-1979)
76. Jorgensen R, Kubale V, Vrecl M, Schwartz TW & Elling CE 2007 Oxyntomodulin differentially affects glucagon-like peptide-1 receptor b-arrestin recruitment and signaling through Ga(s). Journal of Pharmacology and Experimental Therapeutics 322 148-154. (doi:10.1124/jpet.107.120006)
77. Jorgensen NB, Jacobsen SH, Dirksen C, Bojsen-Moller KN, Naver L, Hvolris L, Clausen TR,Wulff BS,Worm D, Lindqvist Hansen D et al. 2012 Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. American Journal of Physiology. Endocrinology and Metabolism 303 E122-E131. (doi:10.1152/ajpendo.00073.2012)
78. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B et al. 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 355 2427-2443. (doi:10.1056/NEJMoa066224)
79. Karra E & Batteram RL 2010 The role of gut hormones in the regulation of body weight and energy homeostasis. Molecular and Cellular Endocrinology 316 120-128. (doi:10.1016/j.mce.2009.06.010)
80. Kerr BD, Flatt PR & Gault VA 2010 (D-Ser2)Oxm(mPEG-PAL): a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochemical Pharmacology 80 1727-1735. (doi:10.1016/j.bcp.2010.08.010)
81. Kervran A, Blache P & Bataille D 1987 Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat. Endocrinology 121 704-713. (doi:10.1210/endo-121-2-704)
82. Kervran A, Dubrasquet M, Blache P, Martinez J & Bataille D 1990 Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney. Regulatory Peptides 31 41-52. (doi:10.1016/0167- 0115(90)90194-2)
83. Kieffer TJ & Habener JF 1999 The glucagon-like peptides. Endocrine Reviews 20 876-913. (doi:10.1210/er.20.6.876)
84. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME & Maggs DG 2008 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 24 275-286. (doi:10.1185/030079908X253870)
85. Koole C,Wootten D, Simms J, Valant C, Sridhar R,Woodman OL,Miller LJ, Summers RJ, Christopoulos A & Sexton PM 2010 Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Molecular Pharmacology 78 456-465. (doi:10.1124/mol.110.065664)
86. Kosinski JR, Hubert J, Carrington PE, Chicchi GG, Mu J, Miller C, Cao J, Bianchi E, Pessi A, Sinharoy R et al. 2012 The glucagon receptor is involved in mediating the body weight lowering effects of oxyntomodulin. Obesity 20 1566-1571. (doi:10.1038/oby.2012.67)
87. Langhans W, Zeiger U, Scharrer E & Geary N 1982 Stimulation of feeding in rats by intraperitoneal injection of antibodies to glucagon. Science 218 894-896. (doi:10.1126/science.7134979)
88. Larsen PJ, Tang-Christensen M, Holst JJ & Orskov C 1997 Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77 257-270. (doi:10.1016/ S0306-4522(96)00434-4)
89. Larsson LI, Holst JJ, Hakanson R & Sundler F 1975 Distribution and properties of glucagon immunoreactivity in the digestive tract of various mammals: an immunohistochemical and immunochemical study. Histochemistry 44 281-290. (doi:10.1007/BF00490364)
90. Lee KC, Chae SY, Kim TH, Lee S, Lee ES & Youn YS 2009 Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regulatory Peptides 152 101-107. (doi:10.1016/ j.regpep.2008.09.008)
91. Le Quellec A, Kervran A, Blache P, Ciurana AJ & Bataille D 1992 Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. Journal of Clinical Endocrinology and Metabolism 74 1405-1409. (doi:10.1210/jc.74.6.1405)
92. Le Quellec A, Clapie M, Callamand P, Lehmann M, Kervran A, Bataille D & Rieu D 1998 Circulating oxyntomodulin-like immunoreactivity in healthy children and children with celiac disease. Journal of Pediatric Gastroenterology and Nutrition 27 513-518. (doi:10.1097/00005176-199811000-00003)
93. Liu YL, Ford HE, Druce MR, Minnion JS, Field BC, Shillito JC, Baxter J, Murphy KG, Ghatei MA & Bloom SR 2010 Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. International Journal of Obesity 34 1715-1725. (doi:10.1038/ijo.2010.110)
94. Liu WJ, Xie SH, Liu YN, KimW, Jin HY, Park SK, Shao YM & Park TS 2012 Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin- induced diabetic rats. Journal of Pharmacology and Experimental Therapeutics 340 248-255. (doi:10.1124/jpet.111.186866)
95. Maida A, Lovshin JA, Baggio LL & Drucker DJ 2008 The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances b-cell function but does not inhibit gastric emptying in mice. Endocrinology 149 5670-5678. (doi:10.1210/en.2008-0336)
96. Marubashi S, Tominaga M, Katagiri T, Yamatani K, Yawata Y, Hara M & Sasaki H 1985 Hyperglycaemic effect of glucagon administered intracerebroventricularly in the rat. Acta Endocrinologica 108 6-10. (doi:10.2337/ db12-1-377)
97. Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F & Reis F 2011 Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Experimental Diabetes Research 2011 162092. (doi:10.1155/2011/162092)
98. Meier JJ, Kemmeries G, Holst JJ & Nauck MA 2005 Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54 2212-2218. (doi:10.2337/diabetes.54.7.2212)
99. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regulatory Peptides 85 9-24. (doi:10.1016/S0167- 0115(99)00089-0)
100. Mighiu PI, Yue JT, Filippi BM & Lam TK 2012 Hypothalamic glucagon signaling regulates glucose production. Diabetes 61 (Suppl 1) A55.
101. Nauck MA 2012 The design of the liraglutide clinical trial programme. Diabetes, Obesity and Metabolism 14 (Suppl 2) 4-12. (doi:10.1111/j.1463- 1326.2012.01573.x)
102. Nauck MA, Kemmeries G, Holst JJ & Meier JJ 2011 Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60 1561-1565. (doi:10.2337/db10-0474)
103. Owens DR 2002 New horizons - alternative routes for insulin therapy. Nature Reviews. Drug Discovery 1 529-540. (doi:10.1038/nrd836)
104. Panchapakesan U, Mather A & Pollock C 2013 Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clinical Science 124 17-26. (doi:10.1042/CS20120167)
105. Parkinson JR, Chaudhri OB, Kuo YT, Field BC, Herlihy AH, Dhillo WS, Ghatei MA, Bloom SR & Bell JD 2009 Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). NeuroImage 44 1022-1031. (doi:10.1016/j.neuroimage.2008.09.047)
106. Parlevliet ET, Heijboer AC, Schroder-van der Elst JP, Havekes LM, Romijn JA, Pijl H & Corssmit EP 2008 Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet. American Journal of Physiology. Endocrinology and Metabolism 294 E142-E147. (doi:10.1152/ ajpendo.00576.2007)
107. Penick SB & Hinkle LE Jr 1961 Depression of food intake induced in healthy subjects by glucagon. New England Journal of Medicine 264 893-897. (doi:10.1056/NEJM196105042641801)
108. Plamboeck A, Holst JJ, Carr RD & Deacon CF 2005 Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48 1882-1890. (doi:10.1007/s00125-005-1847-7)
109. Plamboeck S, Deacon C,Wetter-Gren A, Svendsen L, Meisner S, Hovendahl C, Holst JJ, Knop F & Vilsboll T 2012 Reduced incretin effect in truncal vagotomized subjects. Diabetes 61 (Suppl 1) A95. (doi:10.2337/ db12-1-377)
110. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G et al. 2009 Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58 2258-2266. (doi:10.2337/db09-0278)
111. Pridal L, Deacon CF, Kirk O, Christensen JV, Carr RD & Holst JJ 1996 Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma. European Journal of Drug Metabolism and Pharmacokinetics 21 51-59. (doi:10.1007/BF03190278)
112. Roed SN, Orgaard A, Jorgensen R & De Meyts P 2012 Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity. Frontiers in Endocrinology 3 62. (doi:10.3389/fendo. 2012.00062)
113. Rouille Y, Westermark G, Martin SK & Steiner DF 1994 Proglucagon is processed to glucagon by prohormone convertase PC2 in a TC1-6 cells. PNAS 91 3242-3246. (doi:10.1073/pnas.91.8.3242)
114. Ruddy M, Luncenford J, Li S, Cilissen C, Stoch A, Wagner J, Amatruda J, Herman G & Kaufman K 2011 Inhibition of glucagon-induced hyperglycemia predicts glucose lowering efficacyantagonist, MK-0893, in type 2 diabetes (T2DM). Diabetes 60 (Suppl 1) A85. (doi:10.2337/ db11-1-378)
115. Salter JM 1960 Metabolic effects of glucagon in the Wistar rat. American Journal of Clinical Nutrition 8 535-539.
116. Salter JM, Ezrin C, Laidlaw JC & Gornall AG 1960 Metabolic effects of glucagon in human subjects. Metabolism 9 753-768.
117. Santoprete A, Capito E, Carrington PE, Pocai A, Finotto M, Langella A, Ingallinella P, Zytko K, Bufali S, Cianetti S et al. 2011 DPP-IV-resistant, long-acting oxyntomodulin derivatives. Journal of Peptide Science 17 270-280. (doi:10.1002/psc.1328)
118. Sarson DL, Scopinaro N & Bloom SR 1981 Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. International Journal of Obesity 5 471-480.
119. Schelshorn D, Joly F, Mutel S, Hampe C, Breton B, Mutel V & Lutjens R 2012 Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Molecular Pharmacology 81 309-318. (doi:10.1124/mol.111.074757)
120. Schepp W, Dehne K, Riedel T, Schmidtler J, Schaffer K & Classen M 1996 Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2. Digestion 57 398-405. (doi:10.1159/000201367)
121. Schjoldager BT, Baldissera FG, Mortensen PE, Holst JJ & Christiansen J 1988 Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. European Journal of Clinical Investigation 18 499-503. (doi:10.1111/j.1365-2362.1988. tb01046.x)
122. Schjoldager B, Mortensen PE, Myhre J, Christiansen J & Holst JJ 1989 Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Digestive Diseases and Sciences 34 1411-1419. (doi:10.1007/ BF01538078)
123. Schulman JL, Carleton JL, Whitney G & Whitehorn JC 1957 Effect of glucagon on food intake and body weight in man. Journal of Applied Physiology 11 419-421.
124. Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD, Farb TB, Cao JX, Cox AL, Michael MD et al. 2010 Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59 3099-3107. (doi:10.2337/ db10-0689)
125. Sowden GL, Drucker DJ, Weinshenker D & Swoap SJ 2007 Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 292 R962-R970. (doi:10.1152/ajpregu.00405. 2006)
126. Strazzullo P, Iacone R, Siani A, Barba G, Russo O, Russo P, Barbato A, D'Elia L, Farinaro E & Cappuccio FP 2001 Altered renal sodium handling and hypertension in men carrying the glucagon receptor gene (Gly40Ser) variant. Journal of Molecular Medicine 79 574-580. (doi:10.1007/ s001090100257)
127. Sundby F, Jacobsen H & Moody AJ 1976 Purification and characterization of a protein from porcine gut with glucagon-like immunoreactivity. Hormone and Metabolic Research 8 366-371. (doi:10.1055/s-0028-1093615)
128. Sutherland EW & De Duve C 1948 Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. Journal of Biological Chemistry 175 663-674.
129. Talbot J, Joly E, Prentki M & Buteau J 2012 b-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic b INS832/13 cells. Molecular and Cellular Endocrinology 364 65-70. (doi:10.1016/j.mce.2012.08.010)
130. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J & Vrang N 2000 The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nature Medicine 6 802-807. (doi:10.1038/77535)
131. Thim L & Moody AJ 1981 The amino acid sequence of porcine glicentin. Peptides 2 (Suppl 2) 37-39. (doi:10.1016/0196-9781(81)90007-3)
132. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD et al. 1996 A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 69-72. (doi:10. 1038/379069a0)
133. UKPDS 1995 U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44 1249-1258. (doi:10.2337/diabetes.44.11.1249)
134. Unger RH, Eisentraut AM, McCall MS, Keller S, Lanz HC & Madison LL 1959 Glucagon antibodies and their use for immunoassay for glucagon. Proceedings of the Society for Experimental Biology and Medicine 102 621-623.
135. Unger RH, Eisentraut AM, McCall MS & Madison LL 1961 Glucagon antibodies and an immunoassay for glucagon. Journal of Clinical Investigation 40 1280-1289. (doi:10.1172/JCI104357)
136. Unger RH, Eisentraut AM, McCall MS & Madison LL 1962 Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. Journal of Clinical Investigation 41 682-689. (doi:10.1172/JCI104525)
137. Unger RH, Ohneda A, Valverde I, Eisentraut AM & Exton J 1968 Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose. Journal of Clinical Investigation 47 48-65. (doi:10.1172/JCI105714)
138. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP et al. 2007 Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148 4965-4973. (doi:10.1210/en.2006-0153)
139. Valverde I, Rigopoulou D, Exton J, Ohneda A, Eisentraut A & Unger RH 1968 Demonstration and characterization of a second fraction of glucagonlike immunoreactivity in jejunal extracts. American Journal of the Medical Sciences 255 415-420. (doi:10.1097/00000441-196806000-00007)
140. Vilsboll T, Christensen M, Junker AE, Knop FK & Gluud LL 2012 Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Diabetes, Obesity and Metabolism 14 101-111. (doi:10.1111/j.1463-1326.2012.01579.x)
141. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J & Holst JJ 1993 Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Digestive Diseases and Sciences 38 665-673. (doi:10.1007/BF01316798)
142. Wheeler MBGelling RW, McIntosh CH, Georgiou J, Brown JC & Pederson RA 1995 Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 136 4629-4639. (doi:10.1210/en.136.10.4629)
143. Whitaker GM, Lynn FC, McIntosh CH & Accili EA 2012 Regulation of GIP and GLP1 receptor cell surface expression by N-glycosylation and receptor heteromerization.PLoSONE7 e32675. (doi:10.1371/journal.pone.0032675)
144. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W & Nauck MA 1996 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. Journal of Clinical Endocrinology and Metabolism 81 327-332. (doi:10.1210/jc.81.1.327)
145. Wu YQ, Limburg DC, Wilkinson DE, Jackson P, Steiner JP, Hamilton GS & Belyakov SA 2003 Neuroprotective effects of inhibitors of dipeptidyl peptidase-iV in vitro and in vivo. Advances in Experimental Medicine and Biology 524 351-355. (doi:10.1007/0-306-47920-6_42)
146. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA et al. 2005 Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54 2390-2395. (doi:10.2337/ diabetes.54.8.2390)
147. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS & Bloom SR 2006 Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. International Journal of Obesity 30 1729-1736. (doi:10.1038/ sj.ijo.0803344)
148. Wynne K, Field BC & Bloom SR 2010 The mechanism of action for oxyntomodulin in the regulation of obesity. Current Opinion in Investigational Drugs 11 1151-1157.
149. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA et al. 2003 The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). Journal of Biological Chemistry 278 22418-22423. (doi:10.1074/jbc. M212355200)